CN113507928A - 用于治疗神经障碍的氘代占诺美林的化合物和方法 - Google Patents
用于治疗神经障碍的氘代占诺美林的化合物和方法 Download PDFInfo
- Publication number
- CN113507928A CN113507928A CN202080014856.8A CN202080014856A CN113507928A CN 113507928 A CN113507928 A CN 113507928A CN 202080014856 A CN202080014856 A CN 202080014856A CN 113507928 A CN113507928 A CN 113507928A
- Authority
- CN
- China
- Prior art keywords
- compound
- medicament
- formula
- certain embodiments
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808954P | 2019-02-22 | 2019-02-22 | |
| US62/808,954 | 2019-02-22 | ||
| US201962936358P | 2019-11-15 | 2019-11-15 | |
| US62/936,358 | 2019-11-15 | ||
| PCT/US2020/019193 WO2020172516A1 (en) | 2019-02-22 | 2020-02-21 | Compounds and methods of deuterated xanomeline for treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113507928A true CN113507928A (zh) | 2021-10-15 |
Family
ID=72145029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080014856.8A Pending CN113507928A (zh) | 2019-02-22 | 2020-02-21 | 用于治疗神经障碍的氘代占诺美林的化合物和方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220144817A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3927342A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022523355A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113507928A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020226870A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021016457A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3131128A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020172516A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119161338A (zh) * | 2024-11-25 | 2024-12-20 | 嘉兴安帝康生物科技有限公司 | 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097427A1 (en) * | 2019-11-15 | 2021-05-20 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| WO2023061372A1 (zh) * | 2021-10-14 | 2023-04-20 | 南京迈诺威医药科技有限公司 | 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途 |
| US12269818B2 (en) | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2025174424A1 (en) * | 2024-02-16 | 2025-08-21 | Terran Biosciences Inc. | Analogs of xanomeline, analogs of trospium, and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1777425A (zh) * | 2003-03-28 | 2006-05-24 | 阿卡蒂亚药品公司 | 用于疼痛控制的毒蕈碱性m1受体激动剂 |
| US20170095465A1 (en) * | 2009-07-22 | 2017-04-06 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US20170112820A1 (en) * | 2009-07-22 | 2017-04-27 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2202776A1 (en) * | 1994-10-31 | 1996-05-09 | Franklin Porter Bymaster | Method for treating anxiety |
| JP2000501711A (ja) * | 1995-12-07 | 2000-02-15 | イーライ・リリー・アンド・カンパニー | 疼痛を処置する方法 |
| WO2010102218A1 (en) * | 2009-03-05 | 2010-09-10 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2012033956A1 (en) * | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
-
2020
- 2020-02-21 JP JP2021549216A patent/JP2022523355A/ja active Pending
- 2020-02-21 WO PCT/US2020/019193 patent/WO2020172516A1/en not_active Ceased
- 2020-02-21 AU AU2020226870A patent/AU2020226870A1/en not_active Abandoned
- 2020-02-21 US US17/310,735 patent/US20220144817A1/en not_active Abandoned
- 2020-02-21 BR BR112021016457-0A patent/BR112021016457A2/pt not_active Application Discontinuation
- 2020-02-21 CN CN202080014856.8A patent/CN113507928A/zh active Pending
- 2020-02-21 CA CA3131128A patent/CA3131128A1/en active Pending
- 2020-02-21 EP EP20759391.4A patent/EP3927342A4/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1777425A (zh) * | 2003-03-28 | 2006-05-24 | 阿卡蒂亚药品公司 | 用于疼痛控制的毒蕈碱性m1受体激动剂 |
| US20170095465A1 (en) * | 2009-07-22 | 2017-04-06 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US20170112820A1 (en) * | 2009-07-22 | 2017-04-27 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Non-Patent Citations (1)
| Title |
|---|
| 王世真主编: "《分子核医学》", 31 March 2004, 中国协和医科大学出版社, pages: 417 - 418 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119161338A (zh) * | 2024-11-25 | 2024-12-20 | 嘉兴安帝康生物科技有限公司 | 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用 |
| CN119161338B (zh) * | 2024-11-25 | 2025-06-17 | 嘉兴安帝康生物科技有限公司 | 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用 |
| WO2026108354A1 (zh) * | 2024-11-25 | 2026-05-28 | 杭州安帝康生物科技有限公司 | 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3927342A1 (en) | 2021-12-29 |
| EP3927342A4 (en) | 2022-11-16 |
| JP2022523355A (ja) | 2022-04-22 |
| WO2020172516A1 (en) | 2020-08-27 |
| CA3131128A1 (en) | 2020-08-27 |
| US20220144817A1 (en) | 2022-05-12 |
| AU2020226870A1 (en) | 2021-09-09 |
| BR112021016457A2 (pt) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3810608B1 (en) | Oga inhibitor compounds | |
| US20220144817A1 (en) | Compounds and methods of deuterated xanomeline for treating neurological disorders | |
| CN106905322B (zh) | 吡咯嘧啶五元氮杂环衍生物及其应用 | |
| US20250099596A1 (en) | Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine | |
| US20180311251A1 (en) | Ezh2 inhibitors for treating lymphoma | |
| EP3612519B1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| US11534434B2 (en) | Xanomeline derivatives and methods for treating neurological disorders | |
| EP3544972B1 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| JPH05501540A (ja) | Pcpレセプター・リガンドおよびその用途 | |
| CZ400892A3 (en) | 2-(4-hydroxypiperidino)-1-alkanol derivatives as anti-ischemic agents, process of their preparation and use | |
| US11981681B2 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| EP3372594A1 (en) | Pyrimidine derivative and use thereof | |
| CA3102584A1 (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| CN115141149A (zh) | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 | |
| EP3233077B1 (en) | Dopamine d2 receptor ligands | |
| CN110357858B (zh) | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 | |
| CA3160367A1 (en) | Oga inhibitor compounds | |
| EP0113587B1 (en) | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| EP2643307B1 (fr) | Derives de nitrobenzothiazoles et leur utilisation pour le traitment de la tubercolose | |
| JP2016500096A (ja) | ナトリウム−ヨウ素シンポータの新規阻害剤 | |
| US20040254196A1 (en) | Cinnamaldehyde derivatives inhibiting growth of tumor cell and regulating cell cycle, preparations and pharmaceutical compositions thereof | |
| CN107501270A (zh) | 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用 | |
| EP2325169B1 (en) | Lisofylline analogues and their pharmeacuetical uses | |
| WO2021221953A1 (en) | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same | |
| KR20100040881A (ko) | 전구약물로서 벤라팍신 및 o-데스메틸벤라팍신의 n-옥사이드 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211015 |